Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. cut its stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 26.9% in the third quarter, Holdings Channel reports. The firm owned 15,799 shares of the company’s stock after selling 5,810 shares during the period. Principal Financial Group Inc.’s holdings in Taysha Gene Therapies were worth $32,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. Geode Capital Management LLC lifted its stake in shares of Taysha Gene Therapies by 23.7% during the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock worth $7,163,000 after buying an additional 682,273 shares during the period. Wellington Management Group LLP acquired a new stake in Taysha Gene Therapies during the 3rd quarter worth about $931,000. Bank of New York Mellon Corp purchased a new stake in Taysha Gene Therapies during the 2nd quarter valued at about $1,018,000. Los Angeles Capital Management LLC acquired a new position in shares of Taysha Gene Therapies in the third quarter valued at about $416,000. Finally, Barclays PLC raised its stake in shares of Taysha Gene Therapies by 356.0% in the third quarter. Barclays PLC now owns 247,280 shares of the company’s stock worth $513,000 after purchasing an additional 193,046 shares during the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Analyst Upgrades and Downgrades

TSHA has been the topic of several research reports. Canaccord Genuity Group increased their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Chardan Capital reissued a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, November 14th. JMP Securities restated a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Needham & Company LLC reiterated a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Monday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Taysha Gene Therapies has a consensus rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Trading Down 8.3 %

Shares of NASDAQ:TSHA opened at $1.88 on Wednesday. The firm has a market capitalization of $385.29 million, a price-to-earnings ratio of 2.98 and a beta of 0.95. The business’s 50 day moving average price is $2.10 and its 200-day moving average price is $2.14. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. Taysha Gene Therapies, Inc. has a 1 year low of $1.19 and a 1 year high of $4.32.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.